Archemix Corp.

Novo Nordisk AS has halted one Phase II and two Phase III clinical trials for concizumab, a monoclonal antibody targeting tissue factor pathway inhibitor (TFPI) in the treatment of hemophilia A and B

Ophthotech raised $175 million, mostly in the form of royalty financing from Novo A/S, to fund a 1,900-patient Phase III clinical trial for its anti-platelet-derived growth factor (anti-PDGF) aptamer

Californian biotech company True North Therapeutics has appointed Dr James Gilbert chief medical officer, and raised $22m in its series A financing round to enable it to move its lead candidate into t

The oft-noted inability of life sciences VCs to raise the sums they once did is not just a threat to the sector, but also an opportunity. That’s the view of Deerfield Management, which has set its sig